Author information from the last article
Kreftavdelingen
Senter for lindrende behandling
Sykehuset Innlandet
Forfatterbidrag: tolkning av data, litteratursøk, revisjon og godkjenning av manusrevisjoner.
Arne Kolstad er overlege og professor.
Articles by Arne Kolstad
Allogeneic stem cell transplantation for patients with lymphoma 2011–21
- Hege Melby Frøen,
- Marianne Brodtkorb,
- Harald Holte,
- Arne Kolstad,
- Anders Eivind Myhre,
- Mats Remberger,
- Geir Erland Tjønnfjord,
- Tobias Gedde-Dahl
03.03.2025:
Allogeneic stem cell transplantation (ASCT) is potentially curative for patients with haematologic malignancies, lymphomas and certain non-malignant conditions. However, it carries a risk of severe complications and transplant-related mortality due to organ damage, infection and graft-versus-host...
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987 – 2008
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Anne Kirsti Blystad,
- Unn Merete Fagerli,
- Øystein Fluge,
- Alexander Fosså,
- Jens Hammerstrøm,
- Arne Kolstad,
- Jon Håvard Loge,
- Martin Maisenhølder,
- Bjørn Østenstad,
- Stein Kvaløy,
- Harald Holte
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) is a very intensive, highly specialised and resource-intensive therapy. It has been a treatment option for lymphomas for 25 years. Based on results from prospective studies, it has progressed from being an experimental form of treatment to...
High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment
- Knut Bjøro Smeland,
- Cecilie E. Kiserud,
- Grete F. Lauritzsen,
- Alexander Fosså,
- Jens Hammerstrøm,
- Vidar Jetne,
- Arne Kolstad,
- Gunnar Kvalheim,
- Jon Håvard Loge,
- Turid Løkeland,
- Jon Magnus Tangen,
- Harald Holte,
- Stein Kvaløy
03.09.2013:
High-dose therapy with autologous stem cell support (HDT) for lymphomas has been given in Norway since 1987. The therapy consists of intensive chemotherapy and/or total body irradiation in such high doses that it entails a life-threatening loss of healthy haematopoietic stem cells in the bone marrow...